Israeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat congenital emphysema.
Related posts
$10M For Startup That Cuts Hotels’ Costs
March 28, 2023
Researchers Test High-Capacity Titanium-Air Battery
March 28, 2023
Israel Exports Startup Expertise to Uruguay
March 28, 2023
New Micro-Robot Is The Size Of A Human Cell
March 27, 2023
Facebook comments